How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer

Over the last 20 years, treatment of patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer has considerably improved. The development and addition of (neo)adjuvant trastuzumab to chemotherapy in patients with early HER2+ breast cancer (EHBC) has been shown to pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Untch, Michael, Martin, Miguel, De Laurentiis, Michelino, Gligorov, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593140/
https://www.ncbi.nlm.nih.gov/pubmed/34057699
http://dx.doi.org/10.1007/s40487-021-00153-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593140/
https://www.ncbi.nlm.nih.gov/pubmed/34057699
http://dx.doi.org/10.1007/s40487-021-00153-5

Ejemplares similares